KORU Medical Systems to Report Third Quarter 2024 Financial Results on November 13, 2024
KORU Medical Systems (NASDAQ: KRMD), a medical technology company specializing in subcutaneous infusion solutions, has announced it will release its third quarter 2024 financial results on November 13, 2024. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a corporate update. The call will be accessible to U.S. and Canadian participants at (877)-407-0784 and international callers at (201)-689-8560. A live and archived webcast will be available on the company's investor relations website.
KORU Medical Systems (NASDAQ: KRMD), un'azienda di tecnologia medica specializzata in soluzioni per infusioni sottocutanee, ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 il 13 novembre 2024. L'azienda ospiterà una chiamata e un webcast alle 16:30 ET per discutere i risultati e fornire un aggiornamento aziendale. La chiamata sarà accessibile ai partecipanti degli Stati Uniti e del Canada al numero (877)-407-0784 e ai chiamanti internazionali al numero (201)-689-8560. Un webcast in diretta e registrato sarà disponibile sul sito web delle relazioni con gli investitori dell'azienda.
KORU Medical Systems (NASDAQ: KRMD), una empresa de tecnología médica especializada en soluciones de infusión subcutánea, ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 el 13 de noviembre de 2024. La empresa llevará a cabo una conferencia telefónica y un webcast a las 4:30 p.m. ET para discutir los resultados y proporcionar una actualización sobre la empresa. La llamada estará disponible para los participantes de EE. UU. y Canadá al (877)-407-0784 y para los llamadores internacionales al (201)-689-8560. Un webcast en vivo y grabado estará disponible en el sitio web de relaciones con los inversores de la empresa.
KORU Medical Systems (NASDAQ: KRMD), 피하 주입 솔루션을 전문으로 하는 의료 기술 회사는 2024년 11월 13일에 2024년 3분기 재무 결과를 발표할 것이라고 밝혔습니다. 회사는 오후 4시 30분(동부 표준시)에 결과를 논의하고 기업 업데이트를 제공하기 위해 컨퍼런스 콜과 웹캐스트를 개최합니다. 미국 및 캐나다 참가자는 (877)-407-0784로, 국제 전화자는 (201)-689-8560으로 확인할 수 있습니다. 실시간 및 아카이브된 웹캐스트는 회사의 투자자 관계 웹사이트에서 이용 가능합니다.
KORU Medical Systems (NASDAQ: KRMD), une entreprise de technologie médicale spécialisée dans les solutions d'infusion sous-cutanée, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 le 13 novembre 2024. L'entreprise tiendra une conférence téléphonique et un webinaire à 16h30 (ET) pour discuter des résultats et fournir une mise à jour de l'entreprise. L'appel sera accessible aux participants des États-Unis et du Canada au (877)-407-0784 et aux appelants internationaux au (201)-689-8560. Un webinaire en direct et enregistré sera disponible sur le site Web des relations avec les investisseurs de l'entreprise.
KORU Medical Systems (NASDAQ: KRMD), ein Medizintechnikunternehmen, das auf subkutane Infusionslösungen spezialisiert ist, hat bekannt gegeben, dass es am 13. November 2024 seine Finanzergebnisse für das dritte Quartal 2024 veröffentlichen wird. Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu erörtern und ein Unternehmensupdate zu geben. Die Konferenz ist für Teilnehmer aus den USA und Kanada unter (877)-407-0784 sowie für internationale Anrufer unter (201)-689-8560 erreichbar. Ein Live- und Archiv-Webcast wird auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
Conference Call and Webcast Details
The conference call can be accessed by dialing (877)-407-0784 for participants in the
About KORU Medical Systems
KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Novel Therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241023557077/en/
Investor Contact:
Greg Chodaczek
347-620-7010
investor@korumedical.com
Source: KORU Medical Systems
FAQ
When will KORU Medical Systems (KRMD) report Q3 2024 earnings?
How can I access KORU Medical Systems (KRMD) Q3 2024 earnings call?
What time is KORU Medical Systems (KRMD) Q3 2024 earnings call?
